Press Release
Enigma ML System to demonstrate rapid identification of swine H1n1 influenza at Arab Health 2010
15 January 2010
Oxford & Porton Down, UK – Enigma Diagnostics Limited, the decentralised and pointof-care molecular diagnostics company, announced today it will be attending Arab Health 2010 between 25 - 28 January at the Dubai International Convention and Exhibition Centre, and will demonstrate the Enigma ML system’s capability to detect swine H1N1 influenza from a swab sample in an hour, with no manual processing required.
When faced with patients with flu type symptoms, healthcare professionals need to know immediately if pandemic influenza is the cause so that antiviral therapy can be prescribed. They cannot wait for samples to be despatched to central laboratories for batch testing where results may only be available days later. The Enigma ML will direct decision making at point of care, offer patients immediate relevant treatment and ensure efficient use of emergency resources.
The Enigma ML is a fully automated real-time PCR instrument which can perform molecular diagnostic tests to laboratory standards in as little as 30 minutes. Sample preparation steps are already integrated into the instrument, the user simply loads the sample into a disposable cartridge and the instrument requires no further intervention. The ML uses algorithms to analyse the test data and presents results using a state-of-the-art touch-screen user interface.
The Arab Health Congress is the largest multi-track medical congress and the best scientific and educational event for healthcare professionals in the region. Enigma is participating in MEDLAB 2010 where Dr. Ian George will be presenting “The Future of Molecular Diagnostics and Personalized Medicine”. Enigma will be exhibiting the Enigma ML system at Stand ME50 in the Sheikh Maktoum Hall.
-ENDS‑
Enigma Diagnostics Limited specialises in developing next generation rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings.
Enigma’s innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for decentralized and point-of-care testing providing results from a raw sample in less than 60 minutes. The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high-value Applied Markets. Enigma’s commercialisation strategy is to maximize revenues from a continuous flow of market leading rapid diagnostic point-ofcare instrument and assay platforms, based on unique technologies and underpinned by its broad Intellectual Property portfolio. Enigma will partner with market leaders where global penetration of markets is required and where appropriate, will engage regional partners and build in-house sales and marketing capability to direct distribution of its products.
Enigma has an exclusive license from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded Research. It also has licences from Applied Biosystems and Celera Diagnostics for commercialisation of real-time PCR instruments, and from Roche Molecular Systems to practise HybProbe real-time PCR chemistry for human and veterinary in vitro diagnostics. Enigma’s R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.
Enigma's majority shareholder is Porton Capital, a private equity house which has supported Enigma's development since incorporation in 2004.
For more information visit www.enigmadiagnostics.com
Contacts UK Contact:
Enigma Diagnostics
Deborah Cordingley
Email: deborah.cordingley@enigmadiagnostics.com
Tel:
+44
1235 854076